INTRODUCTION:
Cancer arises from clonal expansion of a single cell. Yet, most human cancers are characterized by extensive intratumor heterogeneity and comprise various subpopulations of cells with distinct phenotypes and biological properties. Intratumor heterogeneity poses major challenges in understanding cancers, managing patients, and designing effective treatment strategies. Functional heterogeneity within individual tumors is partly due to the presence of genetically distinct subclonal cell populations. Furthermore, interactions between cancer cells and the tumor microenvironment can alter the phenotype of cancer cells via nongenetic mechanisms. The combination of cell-intrinsic and cell-extrinsic changes occurring during tumor growth generates functionally distinct subsets of cells that differentially contribute to tumor maintenance.
RATIONALE: In many cancers, phenotypic and functional heterogeneity can be mapped to distinct differentiation states, suggesting that cellular hierarchies established during tumor growth may affect the long-term proliferative potential of cancer cells. To shed light on the mechanisms responsible for the generation of these hierarchies, we searched for epigenetic mechanisms that determine which cancer cells can preserve unlimited proliferative potential, and thus the ability to drive longterm tumor growth, and which cells lose this ability through a differentiation process.
RESULTS:
We found that, in several cancer types, individual tumors exhibit high heterogeneity of the major chromatin protein linker histone H1.0, showing strongly reduced H1.0 levels in cells characterized by long-term selfrenewal ability and tumorigenic potential and higher levels in nontumorigenic cells. Combined analysis of pan-cancer patient data sets and experimental alteration of the H1F0 locus in tumor cells revealed that heterogeneous H1.0 expression patterns are partly due to differential methylation of an enhancer region that dynamically modulates H1.0 expression within tumors. Using a controlled system to model functional intratumor heterogeneity, we showed that maintenance of cell tumorigenic potential required silencing of H1.0 to avoid loss of unlimited proliferative capacity through differentiation. Mechanistically, absence of H1.0 led to destabilization of nucleosome-DNA interactions in AT-rich genomic regions and coordinated derepression of large sets of neighboring genes, resulting in activation of transcriptional programs that support cancer cell self-renewal. Gene expression changes induced by H1.0 loss were reversible, and epigenetic states restricting cell proliferative potential were reestablished upon H1.0 reexpression. In multiple cancer types, in agreement with the observed inhibition of cancer cell self-renewal by H1.0, patients expressing overall strongly reduced levels of H1.0 showed a significantly worse outcome than patients expressing higher H1.0 levels.
CONCLUSION:
Intratumor heterogeneity has emerged as a general feature of cancer, but the molecular features underlying functionally diverse cellular phenotypes have been elusive. Our results uncover epigenetic determinants of tumor-maintaining cells and identify an integral component of chromatin as an important regulator of cell differentiation states within tumors. We propose that only cells insensitive to extracellular differentiation cues, capable of permanently silencing H1.0, can act as selfrenewing tumor-maintaining cells and that such a mechanism supports maintenance of several types of cancer. Our results suggest that intervention aimed at restoring high levels of H1.0 in all cancer cells may enhance the differentiation process that naturally occurs during tumor growth and may be beneficial for therapeutic purposes. † Tumors comprise functionally diverse subpopulations of cells with distinct proliferative potential. Here, we show that dynamic epigenetic states defined by the linker histone H1.0 determine which cells within a tumor can sustain the long-term cancer growth. Numerous cancer types exhibit high inter-and intratumor heterogeneity of H1.0, with H1.0 levels correlating with tumor differentiation status, patient survival, and, at the single-cell level, cancer stem cell markers. Silencing of H1.0 promotes maintenance of self-renewing cells by inducing derepression of megabase-sized gene domains harboring downstream effectors of oncogenic pathways. Self-renewing epigenetic states are not stable, and reexpression of H1.0 in subsets of tumor cells establishes transcriptional programs that restrict cancer cells' long-term proliferative potential and drive their differentiation. Our results uncover epigenetic determinants of tumor-maintaining cells.
C
ancer is a clonal disease originating from a single cell. Yet, most human cancers are characterized by extensive intratumor heterogeneity and comprise various subpopulations of cells with distinct phenotypes and biological properties (1, 2) . Intratumor heterogeneity poses major challenges in understanding cancers, managing patients, and designing effective treatment strategies. Functional heterogeneity within individual tumors is partly due to intercellular genetic variation, which results in the generation of genetically distinct subclonal cell populations (3, 4) . Furthermore, tumors have complex architecture, differing regionally in vessel content, stroma, host infiltrates, and other features that can alter the phenotype of genetically identical cells (5) .
In many cancers, phenotypic and functional heterogeneity can be mapped to distinct differentiation states (5-7), suggesting that epigenetic changes occurring during tumor growth may establish cellular hierarchies within the neoplastic mass, thereby affecting the long-term proliferative potential of cancer cells. In line with this notion, individual tumors have been shown to contain distinct subpopulations of undifferentiated, selfrenewing cells and more differentiated cells, which only have limited proliferative ability (8, 9) . Regardless of their cell of origin, cancer cells endowed with unlimited proliferative potential can be identified by their ability to propagate the disease when transplanted into immunocompromised mice and are referred to as tumor-propagating cells (TPCs) or cancer stem cells (CSCs) (9) . The mechanisms through which epigenetic changes occurring during tumor growth establish differentiation hierarchies and contribute to functional heterogeneity within individual tumors are largely unknown.
We have previously shown that hierarchically organized human primary tumors containing functionally distinct subsets of cancer cells can be generated in a controlled manner using de novo transformed cells. Expression of human telomerase (hTERT) and oncogenic HRAS V12 and concomitant inhibition of p53 and pRB by SV40 T antigens confer tumorigenic potential to various cell types (10) (11) (12) . We have shown that, upon experimental transformation of primary dermal fibroblasts, a subpopulation of cells marked by the CSC marker SSEA1 (13, 14) acquire uncontrolled long-term proliferative potential and multipotency (15 Taking advantage of our ability to generate hierarchically organized human tumors in a controlled manner, here we identify an epigenetic mechanism that establishes intratumor functional heterogeneity. We report that reversible silencing of the linker histone H1.0 (16) affects the differentiation state of cancer cells and contributes to defining which cells within a tumor can maintain long-term self-renewal potential and drive tumor growth. H1.0 is one of multiple H1 variants. Unlike replication-dependent H1 variants, which are mainly expressed in proliferating cells, H1.0 is expressed in both dividing and nondividing cells (16) . H1.0 levels are low in pluripotent cells but accumulate in somatic cells, replacing replication-dependent H1 variants (17) . Here, we demonstrate a critical role for histone H1.0 in inhibiting tumor maintenance.
Results

Heterogeneous levels of H1.0 in individual tumors
We have previously used an engineered system to model functional intratumor heterogeneity of human tumors (see above) (15) . In this system, we have shown by gene expression analysis that selfrenewing tumor cells, which are marked by the surface antigen SSEA1 (SSEA1 + cells), are molecularly distinct from their SSEA1 -differentiated progeny ( fig. S1A ) (15) . Among the differentially expressed genes, H1F0, which encodes histone H1.0, showed consistent down-regulation in SSEA1 + cells compared with SSEA1
-cells in multiple tumors (Fig. 1A and fig. S1B ). Other H1 variants were either expressed at very low levels in all tumor cells (HISTH1A, HISTH1B, HISTH1C, HISTH1D, HISTH1T, H1Foo, H1FNT, and H1FX) or expressed at comparable levels in SSEA1 + and SSEA1 -cells (HISTH1E) (fig. S1B). Analysis of protein levels by quantitative immunofluorescence microscopy of sorted tumor cells and tumor sections confirmed low levels of H1.0 in self-renewing SSEA1 + cells (Fig.  1, B and C, and fig. S1C ). In contrast, SSEA1
-cells expressed heterogeneous, but overall higher, levels of H1.0 (Fig. 1 , B and C, and fig. S1C ), similarly to hTERT-immortalized, nontransformed fibroblasts, from which SSEA1 + cells were originally derived (Fig. 1, B and C) . As a control, comparable levels of H1.4 (HIST1H1E gene product) were detected in SSEA1 + and SSEA1 -cells (Fig. 1B and fig. S1D ). relationship between H1.0 and SSEA1 (Fig. 1, D and E). H1.0 levels negatively correlated with the presence of the mitotic marker phopho-H3S28 in tumors, confirming an association between H1.0 levels and cell proliferative potential ( fig. S2 ).
We next examined H1.0 levels in clinical samples from cancer patients. Glioblastoma multiforme (GBM) is an aggressive brain cancer characterized by highly undifferentiated cells. SSEA1 is an established GBM stem cell marker that enriches for tumor-propagating cells (13, 14) . Singlecell analysis of normal brain and GBM tissue sections by quantitative immunofluorescence microscopy showed overall reduced levels of H1.0, but not H1.4, in cancer samples (Fig. 1, F and G,  and fig. S3A ). However, whereas the SSEA1 -cell population was heterogeneous and included cells expressing H1.0 at comparable levels as normal brain cells (H1F0 high cells), SSEA1 + cells consistently exhibited low levels of the protein (H1F0 low cells) (P < 0.01) (Fig. 1, F and G, and fig. S3A ). Analysis of single-cell RNA-sequencing (RNA-seq) data sets from primary GBMs (2) confirmed these results, because self-renewing GBM cells isolated from multiple tumors (CSCs) showed~10 times lower average levels of H1F0 compared with the whole tumor cell population and~4 times lower levels compared with cells cultured under differentiating conditions (FCS) (Fig. 1H) . Although the average H1F0 levels were variable across GBM samples, the range of H1F0 levels in individual cells was similar in all analyzed tumors ( fig. S3B ), indicating that bulk measurements of the heterogeneous GBM populations mainly reflected the relative abundance of H1F0 high and H1F0 low cells within each population. Furthermore, analysis of gene expression data sets from The Cancer Genome Atlas (TCGA) showed significantly higher bulk levels of H1F0 in lower-grade glioma (LGG) compared with grade 4 GBM (P < 0.001) ( fig. S3C ), suggesting that more aggressive brain tumors contain more H1F0 low cells than well-and moderately differentiated tumors.
Intratumor heterogeneity of H1.0 levels was also observed in other types of cancer. In breast cancer (BRCA), the abundance of H1.0 low cells correlated with histopathological grade, being lower in well-differentiated cancers (grade I) and higher in moderately (grade II) and poorly (grade III) differentiated tumors ( Fig. 1J and fig. S3D ). Levels of H1.0 were particularly low (P < 0.01) in cells expressing ITGA6, a surface antigen marking breast CSCs (18) , which has been shown to have prognostic value as a single parameter (19) (Fig. 1 S6 ). Expression levels are normalized across tissues.
I and K). As a control, H1.4 was not affected in BRCA samples ( fig. S3D ). Similarly, analysis of samples from patients affected by stomach, prostate, uterus, and ovary cancer revealed heterogeneous H1.0 levels in tumor sections, whereas homogeneous high levels were detected in the corresponding normal tissues ( fig. S4A ). A panel of 20 cell lines from 10 cancer types also showed overall reduced levels of H1.0 ( fig. S4 , B and C). In culture, H1.0 levels were sensitive to extracellular signaling, as assessed by treatment of cells with various ligands previously implicated in mediating interactions between cancer cells and the tumor microenvironment. Out of 16 proteins tested, including cytokines, activators or inhibitors of stem cell-related pathways, and growth factors, 9 increased H1.0 levels whereas 2 further lowered them (P < 0.05) ( fig. S4D ). This observation suggests that heterogeneous H1.0 expression patterns within tumors may be the result of differential exposure of cancer cells to extracellular cues. Taken together, these results indicate that several cancer types exhibit highly heterogeneous expression patterns of H1.0 within individual tumors and that cells characterized by an undifferentiated phenotype and expressing functionally validated CSC markers contain particularly low levels of H1.0.
Dynamic H1F0 methylation in tumors
Aberrant DNA-methylation patterns contribute to gene down-regulation in cancer (8) . H1F0 is unmethylated and highly expressed in most adult tissues (figs. S3, A and D, and S4A) (17) ( Fig. 2A  and fig. S5A ). To assess whether DNA methylation affects H1F0 levels within tumors, we performed bisulfite sequencing analysis of the H1F0 locus, comparing self-renewing SSEA1 + cells with the most differentiated tumor cells, characterized by the absence of SSEA1 and reduced levels of the surface antigen CD166 (SSEA1 -/CD166 low ) (15) (see Fig. 3D ). We examined a region spanning 1.1 Kb around the transcriptional start site (TSS) (from -263 to +858), including a CpG island (CGI) ( Fig. 2A) . The CGI in the H1F0 promoter was not methylated in either subset ( fig. S5B ), but a differentially methylated region was identified in the adjacent CGI shore (20) (Fig. 2A) + tumor cells with the DNA methyltransferase inhibitor 5-Aza-2′-deoxycytidine resulted in demethylation of the CGI shore and a progressive increase of H1F0 mRNA with similar kinetics, whereas H1FX, as a control, remained constant ( Fig. 2C and fig.  S5 , C and D; also see methods). Chromatin immunoprecipitation (ChIP) revealed high levels of H3K27ac in the CGI shore, suggesting the presence of an enhancer element (21) (fig. S5, E and F). In agreement, the H1F0 CGI shore showed transactivating potential in reporter assays (Fig.  2D) , and its deletion by clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9-mediated genome editing resulted in decreased levels of endogenous H1F0 mRNA (fig. S5, G and  H) . Furthermore, targeted methylation of the enhancer region by CRISPR-Cas9-DNMT3A (22) (~65% methylation) induced a~45% reduction in H1F0 mRNA levels ( Fig. 2E and fig. S5I ), and in vitro-methylated reporter constructs showed a similar reduction in luciferase assays (Fig. 2F  and fig. S5J ). We conclude that differential methylation of an enhancer controlling H1F0 expression induces H1F0 silencing in self-renewing tumor cells.
We then analyzed expression and methylation data sets from various cancer types generated by TCGA. For each cancer type, correlation between H1F0 mRNA levels measured by RNA-seq and H1F0 methylation assessed by 450 K Infinium microarrays was examined. Similar to what we observed in tumors induced by in vitro-transformed cells, the H1F0 promoter (450 K probes 1 to 4) was not methylated in most patients (Fig. 2, A and G,  and fig. S6 ), whereas a downstream region centered on the CGI shore (450 K probes 5 to 10) showed variable degrees of methylation, which inversely correlated with H1F0 mRNA levels (Fig.  2, A and G, and fig. S6 ). Out of the 27 analyzed types of cancer, 26 showed a significant inverse correlation between H1F0 mRNA levels and DNA methylation (P-value range: P < 2.2 × 10 -16 to P = 0.009) (Fig. 2G and fig. S6 ). Remarkably, the location of the methylated region within H1F0 was the same in all cancers, with the CGI shore (probes 7 and 8) showing the highest correlation with expression levels. In several cohorts, patients characterized by high H1F0 methylation showed a significantly higher proportion of aggressive tumors, such as triple-negative breast cancers and high-grade glioma, kidney cancer, and stomach adenocarcinoma (P-value range: P < 0.0001 to P = 0.016) (table S1). Bisulfite sequencing analysis of multiple cell lines from various cancer types confirmed methylation of the H1F0 CGI shore in clinically derived samples expressing low H1.0 levels (figs. S5K and S4, B and C). We conclude that methylation of the H1F0 CGI shore is associated with silencing of H1F0 in a large variety of cancers.
Chromatin-mediated inhibition of cancer cell self-renewal
To investigate whether changes in H1.0 levels play a functional role in generating functional heterogeneity within tumors, we assessed whether restoring high levels of H1.0 in self-renewing SSEA1 + cells during tumor growth or, conversely, inhibiting reexpression of the protein in their differentiated progeny affects tumor organization and cancer cell long-term proliferative potential. To do so, we introduced into in vitro-transformed cells lentiviral constructs expressing either H1. /SzJ (NSG) mice to induce tumor formation. About 4 weeks after injection, when palpable tumors appear, constitutive expression or knockdown of H1.0 was induced and sustained for~4 weeks while tumors grew (Fig. 3A) . Although analysis of control tumors expressing enhanced green fluorescent protein (EGFP) showed efficient in vivo induction of the Dox-responsive construct (five out of five fluorescent tumors) ( fig. S8F ), when H1.0 was expressed, only 4 out of 11 induced tumors showed higher H1F0 mRNA levels compared with the uninduced tumors (Fig. 3, B and C) . This was not due to inefficient Dox delivery to the tumors, because dissociated tumor cells also failed to induce H1.0 in vitro (fig. S8, G and H) , and suggested that cells expressing constitutively high levels of H1.0 were negatively selected during tumor growth, similarly to what we observed in vitro. As a control, treatment of tumors with Dox for only 3 days resulted in detectable expression of exogenous H1.0 in four out of four tumors ( Fig. 3B and supplementary text) . In contrast, when H1.0 knockdown was induced, no negative selection was observed and all Dox-treated tumors contained high percentages of cells expressing H1.0-targeting shRNAs (9/9) ( fig. S8I) . Thus, constitutively high levels of H1.0 appear to inhibit the long-term proliferative potential of cells within tumors.
To directly assess whether modulation of H1.0 levels affects tumor organization, we first measured the relative abundance of cells expressing markers of an undifferentiated (SSEA1 (Fig. 3D) . Constitutive expression of H1.0 resulted in a significant decrease in the fraction of undifferentiated tumor cells (P = 0.039) and a concomitant increase in differentiated cells (P = 0.005) in the tumors showing increased H1F0 levels (Fig. 3E) . Furthermore, the percentage of self-renewing tumor cells, as measured by clonogenic assays in vitro, was 2-fold lower in induced tumors (P = 0.045) ( (fig. S9A) . Conversely, when knockdown of H1.0 was induced to prevent its accumulation in differentiated cells, the percentage of undifferentiated tumor cells significantly increased (P = 0.005), the fraction of differentiated cells decreased (P = 0.007), and tumors contained~2-fold more selfrenewing cells (P = 0.044) (Fig. 3G fig. S9D, and  supplementary text) . In agreement, tumors expressing constitutive H1.0 showed a lower fraction of mitotic cells, whereas tumors in which H1.0 had been knocked down had a higher mitotic index ( fig. S9, B and C) . (Fig. 3H,  supplementary text, and table S2 ). In line with the notion that even moderate changes in the fraction of self-renewing cancer cells strongly affect long-term tumor growth (18, 25, 26) (supplementary text), transplantation of cells from primary tumors constitutively expressing H1.0 resulted in significantly delayed appearance of secondary tumors compared with control tumors (P < 0.01), whereas faster growth was observed upon transplantation of shH1.0-expressing cells (P < 0.01) (Fig. 3I) . Orthotropic transplantation assays using multiple breast cancer cell lines confirmed these results. Forced expression of H1.0 cDNA in MDA-MB-231 or HCC1954 cells specifically impaired tumor growth, whereas knockdown of the endogenous protein in MDA-MB-231 or HCC-1569 cells resulted in more aggressive tumors (Fig. 3, J and K) . Furthermore, analysis of Doxinduced tumors showed partial negative selection of H10 high cells, confirming the negative impact of H1.0 on cell long-term proliferative potential (fig. S8, J and K). We conclude that H1.0 silencing is required for the ability of cancer cells to selfrenew and that its reexpression in subsets of cells during tumor growth contributes to driving their differentiation and restricting their proliferative potential.
Derepression of adenine-thymine (AT)-rich genes sustains cancer cell self-renewal
To understand how H1.0 affects cancer cell selfrenewal, we employed two inducible shRNAs to knock down H1. showing >2-fold changes ( ), indicating that a significant fraction of genes defining the subset of self-renewing tumor cells, particularly those up-regulated, are regulated by H1.0 (Fig. 4A) . Gene set enrichment analysis (GSEA) confirmed that genes up-regulated upon H1.0 knockdown were particularly relevant for cancer cell self-renewal ability (Fig. 4B) . Several oncogenic gene signatures were enriched in the subset of up-regulated genes, including signatures related to the activation of the oncoproteins KRAS, EGFR, and RAF1 or to the inactivation of the tumor suppressor PTEN (Fig. 4B) . Furthermore, gene signatures important for stem cell maintenance, such as those related to the Polycomb complex components EZH2, EED, BMI1, and SUZ12 (27) , were also enriched among up-regulated genes (Fig. 4B) . Based on GSEA, down-regulated genes did not seem to substantially contribute to the self-renewing phenotype. Thus, loss of H1.0 results in activation of downstream effectors of multiple oncogenic and self-renewal cellular pathways. Interestingly, these genes are not randomly distributed in the genome but are enriched in AT-rich regions ( fig. S11A) .
GSEA also revealed linear proximity of H1.0-sensitive genes along chromosomes. Of 296 positional gene sets, corresponding to genes located in individual chromosomal cytogenetic subbands, 75 were enriched in DOX samples, using either H1.0-targeting shRNA, indicating overall up-regulation of genes located in those bands upon H1.0 knockdown. Conversely, 37 bands negatively correlated with the DOX samples, indicating overall gene down-regulation ( Fig. 4C; fig. S11 of up-regulated genes alternated with down-regulated regions along chromosomes (Fig. 4D) . The differentially expressed domains contained up to 365 genes over several megabases (average genes per domain = 30) ( fig. S11E) . A similar profile was observed 24 hours after Dox induction, when H1.0 levels began to decrease, indicating that transcriptional changes occur rapidly upon H1.0 loss ( fig.  S11, F and G) . Reexpression of H1.0 in washDOX samples, mimicking what happens in differentiated tumor cells, restored transcriptional profiles similar to those detected in uninduced NT samples (Fig.  4E and fig. S11, F and G (28) (Fig. 4D) . In agreement, individual up-regulated genes had significantly lower GC content compared with all Reference Sequence (RefSeq) genes (median %GC: 0.40 versus 0.45, P < 10 × 10 ) (Fig. 4F) , even though the two groups of H1.0-sensitive genes contained a similar proportion of CGI-containing genes ( fig. S11D) . We conclude that cells lacking H1.0 undergo genome-wide changes in gene expression, affecting large gene domains in a coordinated manner. In particular, up-regulation of sets of neighboring AT-rich genes mediating oncogenic cellular responses and stem cell maintenance contributes to the activation and maintenance of transcriptional programs that support uncontrolled self-renewal. These effects are reversible, and reexpression of H1.0 reestablishes gene expression profiles that restrict cell tumorigenic potential.
Destabilized nucleosome-DNA interactions in self-renewing cancer cells
To map genomic regions bound by H1.0 before its down-regulation in self-renewing tumor cells, we performed ChIP-seq analysis of transformed cultured cells. About 120,000 H1.0 peaks were consistently detected in two biological replicates ( fig. S12 , A to C, and table S6), using an H1.0-specific antibody ( fig. S7, C to E) . ChIP-qPCR confirmed accurate detection of H1.0 peaks (fig. S12E ). H1.0 binding sites positively correlated with the histone mark H3K27me3 (Fig. 5A and fig. S12 , B and D). No significant correlation was observed between H1.0 binding profiles and maps of topological associating domains (TADs) (29) (fig. S12D ). H1.0 binding sites were enriched in GC-rich chromosomes and at GC-rich genes ( fig. S12, F and G) , and H1.0 peak density showed a tight linear relationship with GC content in regions with >40% GC (R = 0.86) (Fig. 5B) , indicating that GC content is a major determinant of H1.0 binding sites. Megabase-scale density plots of H1.0 binding sites along chromosomes allowed visualization of the correlation between H1.0 occupancy, GC content, and cytogenetic bands (Fig. 5C and fig. S13A ). In line with the notion that nucleosomes are overall enriched in GC-rich genomic regions, H1.0 occupancy also correlated with nucleosome density (30, 31) (fig. S12H) . We conclude that largescale H1.0 binding profiles are mainly determined by DNA sequence, which affects the broad distribution of nucleosomes. Of note, AT-rich regions characterized by low H1.0 peak density contain the self-renewal-related genes up-regulated upon H1.0 knockdown (Fig. 5C and fig. S13A ).
To gain insights into how H1.0 loss results in up-regulation of AT-rich self-renewal-related genes, we examined H1.0 occupancy around their TSSs. Although up-regulated genes were bound by H1.0 at overall low density (Fig. 5, D and E) , similar to the pattern observed at other AT-rich regions, H1.0 binding sites were highly enriched around the TSS (Fig. 5, F and G and fig. S12, J to L) . In contrast, all RefSeq genes and genes downregulated upon H1.0 knockdown showed an average depletion of H1.0 binding sites around the TSS (Fig. 5F and fig. S12 , J to L). Similar patterns, with enhanced differences, were observed when analyzing the positional gene sets identified as up-regulated by GSEA ( fig. S13, B to D) . Together with the notion that AT-rich regions may be thermodynamically unstable when wrapped around nucleosomes (32, 33) , this observation suggests that H1.0 may repress the AT-rich, self-renewalrelated genes by stabilizing nucleosomes at their promoters. To test this possibility, we assessed changes in genome-wide nucleosome occupancy induced by H1.0 loss by formaldehyde-assisted isolation of regulatory elements-sequencing (FAIREseq) (34) , which allows detection of nucleosomedepleted regions irrespectively of DNA GC content (35, 36) (fig. S14A) . Up-regulated genes specifically showed increased FAIRE signal around the TSS upon H1.0 knockdown using two independent H1.0-targeting shRNAs, indicating decreased nucleosome occupancy (Fig. 5H and figs. S13E and S14, B and C). Similar patterns were observed at distal regulatory regions of H1.0-sensitive genes, identified by comparing an H3K27ac map with an atlas of human enhancers (21) (see methods and fig. S14, F and G) . As a control, knockdown of H1.4, which was depleted at H1.0-sensitive genes ( fig. S12I) , only induced minimal changes in promoter nucleosome occupancy ( fig. S14H ), which did not translate into changes in gene expression ( fig. S10E ). Nucleosome remodeling in the absence of H1.0 did not correlate with increased occupancy of other nucleosome-binding architectural proteins, such as HMGA1, HMGN2, and PARP1 ( fig. S15 ).
In agreement with H1.0 distribution, genomewide analysis of differential FAIRE peaks indicated that altered nucleosome occupancy in the absence of H1.0 depends on GC content, both at a global and local scale. In GC-rich domains [average GC content per 500 base pairs (bp) >0.45], most detected nucleosome-depleted regions were stable and unaffected by H1.0 knockdown (constitutive FAIRE peaks, table S6), and only~25% either appeared or disappeared as a consequence of altered nucleosome occupancy (Fig. 5I) . In contrast, in AT-rich domains (average GC content per 500 bp <0.45),~50% of detected nucleosomedepleted regions showed altered nucleosome occupancy, indicating that nucleosome-DNA interactions in AT-rich regions become particularly unstable in the absence of H1.0 (Fig. 5I) . Furthermore, nucleosome-depleted regions appeared in DNA regions with local minimal GC content, whereas they disappeared from regions of local maximal GC content, suggesting that nucleosomes forced to occupy regions with higher AT content, in the absence of H1.0 moved to locations with higher GC content (Fig. 5J and fig. S14D ).
Mapping of H3K27ac and H3K27me3 by ChIPseq indicated that altered nucleosome occupancy induced by H1.0 loss was uncoupled from changes in histone modifications. Most appearing or disappearing FAIRE peaks were located within nonacetylated chromatin ( fig. S14E ), suggesting that alterations in nucleosome occupancy were not a consequence of transcription. Furthermore, upregulated self-renewal-related genes did not show significant differences in H3K27ac and H3K27me3 at their promoters upon H1.0 knockdown compared with down-regulated genes (P > 0.05) (Fig.  5K ), indicating that changes in gene expression were a direct consequence of altered nucleosome occupancy. Taken together, these results suggest that loss of H1.0 destabilizes nucleosome-DNA interactions in AT-rich genomic regions and increases accessibility to regulatory elements important for cellular self-renewal.
Low H1F0 levels predict negative patient outcome in multiple cancer types
To assess the clinical relevance of H1.0 alterations, we examined whether H1F0 levels stratify cancer patients. Kaplan-Meier and multivariate analysis of three GBM data sets showed a significant correlation between low H1F0 levels and negative patient outcome (P < 0.05) (Fig. 6A and  fig. S16C ), revealing a prognostic value for H1F0. Low H1F0 levels also predicted poor patient prognosis in three BRCA data sets (Fig. 6B) . Importantly, H1F0 correlated with BRCA patient survival independently of estrogen receptor (ER), progesterone receptor (PR), erb-b2 receptor tyrosine kinase 2 (Her2) and lymph node status and effectively stratified patients typically associated with negative outcome (ER-or PR-negative and lymph nodepositive patients) (P < 0.05) ( fig. S16, A and C) . Furthermore, H1F0 expression showed no significant association with breast cancer subtype, which strongly affects patient outcome ( fig. S16B) . Analysis of 17 other types of cancers using TCGA data sets showed a significant correlation between low H1F0 levels and poor patient prognosis also in melanoma (SKMC), liver cancer (LIHC), kidney cancer (KIRP), and low-grade glioma (LGG), independently of other clinically relevant features (Fig. 6C and fig. S16C ). As controls, other H1 variants either did not stratify patients or correlated with patient survival in an opposite manner compared with H1F0 ( fig. S17) . Thus, alterations in H1.0 levels are clinically relevant in multiple cancer types.
Discussion
Heterogeneity among cancer cells within individual tumors has emerged as a general feature of cancer, with critical implications for cancer diagnosis and treatment (4, 9) . Increasing evidence points to the existence of both genetic and nongenetic sources of intratumor heterogeneity (4, 5, 14, 37, 38) , but the molecular features underlying functionally diverse cellular phenotypes have been elusive. Cell-to-cell signaling pathways, such as Wnt, Tgfb, and Notch pathways, have been shown to play critical roles in driving functional heterogeneity within tumors (38) , but very little is known about the downstream, cell-intrinsic mechanisms that translate signaling into differential cell function. Here, we show that distinct epigenetic states, determined by an integral component of chromatin, define cellular subpopulations that differentially contribute to tumor maintenance. The observation that experimental modulation of epigenetic states affects the balance between selfrenewing and differentiated cancer cells demonstrates that chromatin-based mechanisms mediating differentiation programs play a key role in specifying tumor organization and affecting tumor maintenance. In line with the notion that epigenetic mechanisms acting during tumor growth may be dominant over genetic alterations that initiate the disease (37, 39) , we show that subsets of cells that stably silence H1.0 preserve their ability to proliferate indefinitely, whereas cells that reexpress the protein and, as a consequence, repress oncogenic gene networks acquire a differentiated phenotype characterized by limited proliferative potential. Reversible changes in H1.0 levels may be due to interactions of cancer cells with the tumor microenvironment (38) . In line with this notion, H1.0 expression responds to a variety of extracellular cues, many of which are associated with cellular differentiation (40, 41) (fig.  S4D ). It is likely that, at least in the early stages of tumor development, cancer cells may be exposed to differentiation stimuli that support normal tissue homeostasis, and subsets of cells may respond to such stimuli, changing their epigenetic landscape, partly through H1.0 and losing self-renewal potential. Thus, H1.0 may act as a downstream effector of extracellular signaling inhibiting cancer cell self-renewal.
Our results suggest that numerous cancer types may share similar epigenetic heterogeneity. Numerous solid tumors show heterogeneity of H1.0, and a regulatory region within the H1F0 gene shows variable degrees of DNA methylation in 26 types of cancers, correlating with H1F0 expression levels. Furthermore, low H1F0 levels are independent predictors of poor patient outcome in six prevalent cancer types. Importantly, the molecular mechanism through which H1.0 restricts cell proliferative potential is largely dependent on DNA sequence and GC content, suggesting that changes in H1.0 levels may have similar consequences in various cell types. We show that silencing of H1F0 supports cancer cell selfrenewal by inducing simultaneous derepression of downstream effectors of oncogenic and stem cell-related pathways located in AT-rich genomic regions. AT-rich regions are known to poorly incorporate into nucleosomes, partly because of their inherent relative rigidity and difficulty to bend around the core histone particle (30) (31) (32) (33) . Thus, it is conceivable that AT-rich regions may be particularly dependent on the linker histone to stabilize nucleosome positioning at unfavorable sequences, especially when nucleosomes are forced to occupy promoters of genes that must be repressed. Indeed, we find lower nucleosome occupancy at AT-rich gene promoters in the absence of H1.0, correlating with enhanced transcription.
In conclusion, our results uncover epigenetic determinants of tumor-maintaining cells and identify an integral component of chromatin as an important regulator of cell differentiation states within tumors. We propose that only cells insensitive to extracellular differentiation cues, capable of permanently silencing H1.0, can act as self-renewing tumor-maintaining cells and that such a mechanism supports maintenance of several types of cancer. Our results suggest that intervention aimed at restoring high levels of H1.0 in all cancer cells may enhance the differentiation process that naturally occurs during tumor growth and may be beneficial for therapeutic purposes.
Materials and methods summary Cell lines and constructs
Growth conditions of all cell lines used in the study are listed in table S7. Inducible cell lines were generated by introducing lentiviral constructs (original or modified pTRIPZ, Open Biosystems) expressing specific cDNAs or shRNAs, or control SCIENCE sciencemag.org 30 fig. S16 . plasmids into in vitro-transformed fibroblasts (15) or breast cancer cells lines. All cancer cell lines were sourced from the Crick Institute common repository, authenticated by STR profiling, and tested for mycoplasma. Cell proliferation rate was measured using the 96 Aqueous One Solution kit (Promega). For details on cell lines generation, see the supplementary materials (SM).
Patient samples
Normal brain and GBM (grade 4 astrocytoma) tissue sections were obtained from the Whittington tissue bank (UCL license number: 12055, three normal and four tumors) and from US Biomax (tissue microarray GL806b). All other tissue sections were obtained from US Biomax (tissue microarrays: BR1053b, BCN962). Single-cell RNA-seq data of GMB tumors was downloaded from GEO series GSE57872 (2) . DNA methylation and survival analysis were performed using TCGA data sets. For details on patients used in the study, see SM.
Protein immunodetection
Western blot analysis, flow cytometric analysis, cell sorting, and immunofluorescence microscopy of cultured or sorted tumor cells were performed as previously described (15) using anti-H1.0 (Millipore, raised in mouse, clone 3H9, 1:300, originally produced in M. Bustin's laboratory) (42) and other antibodies detailed in SM. Recombinant proteins were purchased from Peprotech. Quantification of the fluorescent signal was performed using Metamorph software or with HCS Studio Cell Analysis Software. For details about staining procedures, see SM.
Tumorigenicity assays
Tumor formation in NSG mice, tumor dissociation, limiting dilution transplantation assays, soft agar assays and proliferation assays were performed as previously described (15) . For experiments requiring in vivo modulation of H1 variants in established tumors, cells infected with inducible constructs were injected intradermally into NSG mice (2000 transformed cells and 100,000 hTERTfibroblasts as carrier cells) in the uninduced state to induce tumor formation (10 injections per condition). When tumors first became palpable, typically after 4 weeks, doxycycline treatment (2mg/ml Dox in drinking water supplemented with 1% sucrose, changed every 2 to 3 days) was started and sustained for about a month until tumors were collected and analyzed as detailed in SM. Animal studies were conducted in agreement with the approved NCI animal protocol LRBGE-007 and the Crick project license PPL 70/8167.
DNA methylation analysis
For bisulfite sequencing analysis, genomic DNA was treated for bisulfite conversion using EZ DNA Methylation-Direct Kit (Zymo research) according to the manufacturer's instructions. Three regions of H1F0 (CGI_1, CGI_2, and CGIshore) were amplified by PCR (primer sequences in table S8) from bisulfite-treated DNA and cloned into pCR 2.1 Topo vector. 15 to 20 colonies were sequenced for each region. For 5-Aza-2′-deoxycytidine (5-Aza) treatment, SSEA1 + cells isolated from a tumor were treated with 5nM 5-Aza (Sigma) or DMSO as a control (Fisher Chemical) for up to 14 days. Higher concentrations of 5-Aza were toxic to the SSEA1+ cells. For analysis of TCGA samples, gene expression (Illumina HiSeq RNA-seq) and DNA methylation (Illumina 450K Infinium analysis) data sets from individual cancers downloaded from the UCSC Cancer browser https:// genome-cancer.ucsc.edu were analyzed as detailed in SM.
CGI shore functional assays
Luciferase assays were performed using the Nano-Glo Dual-Luciferase reporter assay system (Promega) comparing the H1F0 CGI shore and two previously published DNA fragments showing no transactivation potential (21, 43) . Deletion of the endogenous H1F0 CGI shore was carried out by CRISPR-Cas9-mediated genome editing using two sgRNAs flanking the CGI shore (table  S8) . Clones with homozygous deletions of the H1F0 CGI shore were analyzed by qRT-PCR using primers located downstream of the deletion. For heterozygous clones, allele-specific primers probing either the deleted or the full-length mRNA were used (table S8) . To induce targeted methylation of the endogenous H1F0 CGI shore, cells were transiently transfected with plasmids encoding either WT or ANV mutant Cas9-DNMT3A (22) and a pool of four sgRNAs targeting H1F0 CGI shore (table S8) . For details on luciferase assays and CRISPR-mediated alterations of the H1F0 CGI shore, see SM.
RNA-seq analysis and GSEA RNA libraries prepared using TruSeq Stranded Total RNA-Seq Library Prep (Illumina) were sequenced on a HiSEq. 2500 sequencer (table S6) . Differentially expressed genes were defined as those showing statistically significant differences (FDR <0.05) using both H1.0-targeting shRNAs. Genome-wide expression plots were generated using similar methods to those described in (44) . Deviation from random distribution was calculated on raw, unsmoothed data by performing a Monte Carlo simulation in which genes where randomly shuffled along chromosomes (1000 iterations). GSEA was performed using GSEA software (version 2.1.0, Broad Institute). FPKM values for NT and DOX samples were provided to the algorithm and tested for enrichment of oncogenic signatures from the MSigDB or custom-made positional gene sets generated based on RefSeq genes and cytogenetic sub-bands coordinates downloaded from the UCSC genome browser. For details on RNA-seq analysis, GSEA, and validation by qRT-PCR, see SM.
ChIP-seq analysis
ChIP was performed on in vitro-transformed fibroblasts using an anti-H1.0 antibody (Millipore, 05-629, originally generated in M. Bustin's laboratory) (42) , and other antibodies detailed in SM. Multiplexed libraries were sequenced on a HiSEq. 2500 using either 50-bp single end or 101-bp pairedread runs (table S6) . Peak detection for H1.0 was performed with a custom-made algorithm as detailed in SM.
FAIRE-seq analysis
Cells were processed and analyzed as previously described (45) . FAIRE peaks were called using MACS-2.0.10 in paired-end mode using broad settings with a bandwidth of 300 bp, normalizing each sample to its own background as described (45) . The top 100,000 peaks (based on adjusted P value) were selected for each replicate, and those common to both (with a 20% reciprocal overlap) were selected for downstream analysis. Differential FAIRE peaks analysis was performed using DiffReps (46) . For details on FAIRE-seq analysis, see SM.
Survival analysis
Survival analysis was performed on all TCGA data sets containing more than 200 patients. Patients were ranked based on H1F0 expression, and the top and bottom tertile were compared with respect to vital status by Kaplan-Meier analysis. Log-rank test was used to assess statistical significance of the differences between patient groups. Additional data sets for GBM and BRCA were analyzed as validation. Multivariate analysis and chi-square tests were performed to assess the relationship between H1.0 and other clinically relevant features. For details on the survival analysis, see SM.
Statistical analysis
Unless otherwise stated in figure legends, data are presented either as individual samples or as mean ± standard error of the mean (SEM) of multiple replicates, with N indicated in the figure legend. In box plots, the boundary of the box closest to zero indicates the 25th percentile, a line within the box marks the median, and the boundary of the box farthest from zero indicates the 75th percentile. Whiskers (error bars) above and below the box indicate the 95th and 5th percentiles. Outliers are plotted as dots. The statistical test used for each comparison, whether adjustment for multiple corrections was performed, and the P value are indicated in the corresponding figure legends.
